Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 201–300 of 1,004

TNF Counterbalances the Emergence of M2 Tumor Macrophages
Kratochvill, F., Neale, G. A. M., Haverkamp, J. M., de Velde, L.-A. V., Smith, A. M., Kawauchi, D., McEvoy, J. D., Roussel, M. F., Dyer, M. A., Qualls, J. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.033 · Cited by 291
Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth
Yazdani, H. O., Roy, E., Comerci, A. J., van der Windt, D. J., Zhang, H., Huang, H., Loughran, P., Shiva, S., Geller, D. A., Bartlett, D. L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0800 · Cited by 280
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy
Pascual-García, M., Bonfill-Teixidor, E., Planas-Rigol, E., Rubio-Perez, C., Iurlaro, R., Arias, A., Cuartas, I., Sala-Hojman, A., Escudero, L., Martínez-Ricarte, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10369-9 · Cited by 262
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A. M., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 287
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P. H., Cavanaugh, M. E., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 281
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis
Wu, L., Zhang, X., Zheng, L., Zhao, H., Yan, G., Zhang, Q., Zhou, Y. J., Lei, J., Zhang, J., Wang, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0261 · Cited by 277
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“In addition, CAR-Ms promoted an inflammatory state within the TME and were capable of antigen cross-presentation to tumor-specific CD8 + T cells [135].”
Background
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Ock, C.-Y., Keam, B., Kim, S., Lee, J., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D., Chung, D. H., & Heo, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2834 · Cited by 269
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
Parra, E. R., Uraoka, N., Jiang, M., Cook, P., Gibbons, D. L., Forget, M., Bernatchez, C., Haymaker, C., Wistuba, I. I., & Rodriguez‐Canales, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-13942-8 · Cited by 273
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Wang, D., Wang, T., Yu, H., Feng, B., Zhou, L., Zhou, F., Hou, B., Zhang, H., Luo, M., & Li, Y. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6584 · Cited by 265
Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy
Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R., & Mooney, D. J. (2017) · Advanced Biosystems · doi:10.1002/adbi.201600013 · Cited by 259
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 270
STING activation in cancer immunotherapy
Su, T., Zhang, Y. L., Valerie, K. C., Wang, X., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 262
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 261
Protective and therapeutic potential of ginger ( Zingiber officinale ) extract and [6]‐gingerol in cancer: A comprehensive review
de Lima, R. M. T., dos Reis, A. C., de Menezes, A. P. M., Santos, J. V. D. O., Filho, J. W. G. D. O., Ferreira, J. R. D. O., de Alencar, M. V. O. B., da Mata, A. M. O. F., Khan, I. N., Islam, M. A., et al. (2018) · Phytotherapy Research · doi:10.1002/ptr.6134 · Cited by 267
Radiation and Inflammation
Schaue, D., Micewicz, E. D., Ratikan, J. A., Xie, M. W., Cheng, G., & McBride, W. H. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.007 · Cited by 268
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 251
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
Chae, Y. K., Chang, S., Ko, T., Anker, J. F., Agte, S., Iams, W. T., Choi, W. M., Lee, K., & Cruz, M. R. D. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21061-1 · Cited by 261
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Aval, L. M., Pease, J. E., Sharma, R., & Pinato, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103323 · Cited by 253
STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment
Ohkuri, T., Ghosh, A., Kosaka, A., Zhu, J., Ikeura, M., David, M., Watkins, S. C., Sarkar, S. N., & Okada, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0099 · Cited by 255
Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma
Castino, G. F., Cortese, N., Capretti, G. L., Serio, S., Caro, G. D., Mineri, R., Magrini, E. I., Grizzi, F., Cappello, P., Novelli, F., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1085147 · Cited by 242
Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma
Li, Q., Liu, X., Wang, D., Wang, Y., Lu, H., Wen, S., Fang, J., Cheng, B., & Wang, Z. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-00092-3 · Cited by 254
Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment
Wang, S., Li, F., Ye, T., Wang, J., Lyu, C., Qing, S., Ding, Z., Gao, X., Jia, R., Yu, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6981 · Cited by 240
Assessing the interactions between radiotherapy and antitumour immunity
Grassberger, C., Ellsworth, S. G., Wilks, M. Q., Keane, F. K., & Loeffler, J. S. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0238-9 · Cited by 244
Gene therapy for cancer: present status and future perspective
Amer, M. H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-27 · Cited by 264
Metallic nanoparticles for cancer immunotherapy
Evans, E. R., Bugga, P., Asthana, V., & Drezek, R. A. (2017) · Materials Today · doi:10.1016/j.mattod.2017.11.022 · Cited by 248
Radiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
Emerging immunotherapy for HCC: A guide for hepatologists
Foerster, F., Gairing, S. J., Ilyas, S. I., & Galle, P. R. (2022) · Hepatology · doi:10.1002/hep.32447 · Cited by 245
The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 261
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille‐Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 249
Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations
He, D., Wang, D., Lü, P., Yang, N., Xue, Z., Zhu, X., Zhang, P., & Fan, G. (2020) · Oncogene · doi:10.1038/s41388-020-01528-0 · Cited by 249
Dendritic cells direct circadian anti-tumour immune responses
Wang, C., Barnoud, C., Cenerenti, M., Sun, M., Caffa, I., Kizil, B., Bill, R., Liu, Y., Pick, R., Garnier, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05605-0 · Cited by 253
Wnt signaling pathway in cancer immunotherapy
Zhou, Y., Jiang, X., Luo, H., Meng, X., Chen, M., & Zhu, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 241
Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity
Zhang, L., & Romero, P. J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.11.005 · Cited by 241
Natural Killer T Cells in Cancer Immunotherapy
Nair, S., & Dhodapkar, M. V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01178 · Cited by 231
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
Marshall, E. A., Ng, K. W., Kung, S. H. Y., Conway, E. M., Martínez, V. D., Halvorsen, E. C., Rowbotham, D. A., Vucic, E. A., Plumb, A. W., Becker‐Santos, D. D., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0551-1 · Cited by 233
Engineering universal cells that evade immune detection
Lanza, R., Russell, D. W., & Nagy, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0200-1 · Cited by 238
Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Engelhard, V. H., Rodriguez, A. B., Mauldin, I. S., Woods, A. N., Peske, J. D., & Slingluff, C. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701269 · Cited by 231
Mobile Microrobots for Active Therapeutic Delivery
Erkoc, P., Yasa, I. C., Ceylan, H., Yaşa, Ö., Alapan, Y., & Sitti, M. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800064 · Cited by 230
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 235
Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients
Wu, W., Sun, H.-W., Chen, H., Liang, J., Yu, X.-J., Wu, C., Wang, Z., & Zheng, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320753111 · Cited by 231
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Warming the mouse to model human diseases
Ganeshan, K., & Chawla, A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.48 · Cited by 222
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 227
Tumor innervation: peripheral nerves take control of the tumor microenvironment
Gysler, S. M., & Drapkin, R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147276 · Cited by 230
Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
Michea, P., Noël, F., Zakine, È., Czerwińska, U., Sirven, P., Abouzid, O., Goudot, C., Scholer‐Dahirel, A., Vincent‐Salomon, A., Reyal, F., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0145-8 · Cited by 231
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11782-w · Cited by 211
Self-citation
ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence
Chevalier, M. F., Trabanelli, S., Racle, J., Salomé, B., Cesson, V., Gharbi, D., Bohner, P., Domingos‐Pereira, S., Dartiguenave, F., Fritschi, A.-S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89717 · Cited by 218
Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control
Zhen, Z., Tang, W., Wang, M., Zhou, S., Wang, H., Wu, Z., Hao, Z., Li, Z., Liu, L., & Xie, J. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b04150 · Cited by 222
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 224
Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment
Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 221
Nanoscale Metal–Organic Frameworks for Cancer Immunotherapy
Ni, K., Luo, T., Nash, G. T., & Lin, W. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00313 · Cited by 218
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
Heterogeneity in immune responses: from populations to single cells
Satija, R., & Shalek, A. K. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.03.004 · Cited by 215
Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ
Davis, R. J., Moore, E. C., Clavijo, P. E., Friedman, J., Cash, H. A., Chen, Z., Silvin, C., Waes, C. V., & Allen, C. T. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2534 · Cited by 217
The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment
Laha, D., Grant, R., Mishra, P., & Nilubol, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656908 · Cited by 219
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 218
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Gadgeel, S. M., Pennell, N. A., Fidler, M. J., Halmos, B., Bonomi, P., Stevenson, J. P., Schneider, B. J., Sukari, A. W., Ventimiglia, J., Chen, W., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.002 · Cited by 211
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. H. H. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 215
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 229
The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer
Savant, S. S., Sriramkumar, S., & O’Hagan, H. M. (2018) · Cancers · doi:10.3390/cancers10080251 · Cited by 215
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Williams, J. B., Horton, B. L., Zheng, Y., Duan, Y., Powell, J. D., & Gajewski, T. F. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160485 · Cited by 213
Self-citation
MicroRNA regulons in tumor microenvironment
Suzuki, H. I., Katsura, A., Matsuyama, H., & Miyazono, K. (2014) · Oncogene · doi:10.1038/onc.2014.254 · Cited by 210
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 216
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Espinosa-Carrasco, G., Chiu, E. Y., Scrivo, A., Zumbo, P., Dave, A., Betel, D., Kang, S. W., Jang, H.-J., Hellmann, M. D., Burt, B. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.025 · Cited by 211
An expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 215
Fragmented Sleep Accelerates Tumor Growth and Progression through Recruitment of Tumor-Associated Macrophages and TLR4 Signaling
Hakim, F., Wang, Y., Zhang, S. X. L., Zheng, J., Yolcu, E. S., Carreras, A., Khalyfa, A., Shirwan, H., Almendros, I., & Gozal, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3014 · Cited by 206
The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis
Liu, W., Zhang, L., Xu, H., Li, Y., Hu, C.-M., Yang, J., & Sun, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092736 · Cited by 209
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Rangraze, I. R., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A. A., Rizzo, M., El‐Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 212
Neutrophils as active regulators of the immune system in the tumor microenvironment
Shaul, M. E., & Fridlender, Z. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr1216-508r · Cited by 207
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, R., Al‐Khadairi, G., & Decock, J. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 209
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response
Cohen, M., Giladi, A., Barboy, O., Hamon, P., Li, B., Zada, M., Gurevich‐Shapiro, A., Beccaría, C. G., David, E., Maier, B. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00338-5 · Cited by 204
Intermittent Hypoxia-induced Changes in Tumor-associated Macrophages and Tumor Malignancy in a Mouse Model of Sleep Apnea
Almendros, I., Wang, Y., Becker, L., Lennon, F. E., Zheng, J., Coats, B. R., Schoenfelt, K. S., Carreras, A., Hakim, F., Zhang, S. X., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1830oc · Cited by 201
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
Sun, C., Sun, H., Zhang, C., & Tian, Z. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.91 · Cited by 201
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
Sarhan, D., Cichocki, F. M., Zhang, B., Yingst, A. M., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 198
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Jin, H., Wan, C., Zou, Z., Zhao, G., Zhang, L., Geng, Y., Chen, T., Huang, A., Jiang, F., Feng, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08148 · Cited by 201
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R. S., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00105 · Cited by 204
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance
Palmer, D. C., Guittard, G. C., Franco, Z., Crompton, J. G., Eil, R. L., Patel, S. J., Ji, Y., van Panhuys, N., Klebanoff, C. A., Sukumar, M., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150304 · Cited by 196
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 204
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
Ilié, M., Szafer‐Glusman, E., Hofman, V., Chamorey, E., Lalvée, S., Selva, É., Leroy, S., Marquette, C., Kowanetz, M., Hedge, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx636 · Cited by 199
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Büchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 201
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210
Emerging Targeted Therapies for HER2-Positive Breast Cancer
Mercogliano, M. F., Bruni, S., Mauro, F. L., & Schillaci, R. (2023) · Cancers · doi:10.3390/cancers15071987 · Cited by 214
A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer
Kulkarni, A. A., Chandrasekar, V., Natarajan, S. K., Ramesh, A., Pandey, P. R., Nirgud, J., Bhatnagar, H., Ashok, D., Ajay, A. K., & Sengupta, S. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0254-6 · Cited by 193
The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille‐Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 199
Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers
Bian, W., Wang, Y., Pan, Z., Chen, N., Li, X., Wong, W., Liu, X., He, Y., Zhang, K., & Lu, Y. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01903 · Cited by 198
Cell primitive-based biomimetic functional materials for enhanced cancer therapy
Luo, G., Chen, W., Zeng, X., & Zhang, X. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00152j · Cited by 194
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieslik, M. P., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 193
Current state of immunotherapy for non-small cell lung cancer
Malhotra, J. D., Jabbour, S. K., & Aisner, J. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.01 · Cited by 193
Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling
Ham, S., Lima, L. G., Chai, E. Z. P., Muller, A., Lobb, R. J., Krumeich, S., Wen, S., Wiegmans, A. P., & Möller, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00871 · Cited by 190
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 203
Impact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 201

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks